"What do you dream will happen by 2025?" "That fewer people will have to say goodbye too soon to people that they love."" Theranos, a healthcare start-up, that promised to revolutionize blood testing, diagnoses, and the treatment of diseases, that was founded by Elizabeth Holmes, a Stanford dropout, in 2003, when she was just 19 years old.
Elizabeth Holmes was named one of the richest women and youngest self-made female billionaire in the United States by Forbes. She had a 50 % stake in Theranos, worth $4.5 billion, which was valued at $9 billion at that point. She was compared to the geniuses of Western culture like Archimedes and Beethoven. After fifteen years of operating Theranos, it turned out; "Holmes was just another start-up scammer who used blustery talk and an unclear vision of her product to sell investors on a relatively flimsy concept".
Table of Contents
INTRODUCTION
IDEATION, PRODUCT & TEAM
RISE TO THE PEAK
WHISTLEBLOWERS, DOWNFALL & FAILURES
CONCLUSION & PERSONAL OPINION
Research Objectives and Core Themes
This case study analyzes the rise and fall of the healthcare startup Theranos, examining the factors that enabled a multi-billion dollar valuation despite a fraudulent technological foundation, and exploring the ethical and management failures that led to its eventual collapse.
- The role of charismatic leadership and persuasive communication in securing investor capital.
- Corporate governance deficiencies, including the lack of relevant expertise within the board of directors.
- The impact of internal whistleblowers and investigative journalism on corporate accountability.
- The ethical implications of prioritizing growth over patient safety and product viability.
Excerpt from the Case Study
IDEATION, PRODUCT & STAFF
The idea for Theranos comes from her fear of needles. She pledged that the method would liberate people from the tyranny of venous blood draws (Ledford, H., 2019).
The company’s blood-testing machine Edison was able, based on Holmes’ statement, to gather vast amounts of data through a minimal amount of blood. (Shorey, E., 2019). Further, Theranos state that the machine was able to perform hundreds of tests (Heaven, D., 2019).
Theranos has been awarded five patents. Two patents described a system that enables the collection of a smaller volume of blood than allowed by current methods of testing. Another patent uses sonication technology to extract and disrupt various particles in a blood sample (Cao, S., 2019).
Most tests never worked. The functionality of Edison was currently impossible. The real machine also pretended things worked when they did not. Holmes sold people on this before it had made one. Many employees knew that Edison could not be built (Heaven, D., 2019).
Summary of Chapters
INTRODUCTION: Provides an overview of Elizabeth Holmes and the founding of Theranos, framing the company's initial promise against its ultimate reality as a fraudulent enterprise.
IDEATION, PRODUCT & TEAM: Details the original vision of the company, the development of the Edison machine, the recruitment of a high-profile board of directors, and the acquisition of substantial investor capital.
RISE TO THE PEAK: Outlines the company's expansion, including the partnership with Walgreens and the peak valuation of $9 billion, despite the lack of functional technology.
WHISTLEBLOWERS, DOWNFALL & FAILURES: Chronicles the investigation by journalists and employees, the subsequent legal and financial repercussions, and the eventual dissolution of the firm.
CONCLUSION & PERSONAL OPINION: Offers a reflective synthesis of the leadership, governance, and management errors that doomed the company.
Key Keywords
Theranos, Elizabeth Holmes, blood testing, Edison machine, Silicon Valley, corporate fraud, venture capital, governance, ethics, whistleblowers, board of directors, Walgreens, biotechnology, regulation, startup failure.
Frequently Asked Questions
What is the core subject of this case study?
The study examines the lifecycle of Theranos, a startup that claimed to revolutionize blood testing but ultimately collapsed due to fraud and unproven technology.
What are the primary themes discussed in the paper?
The paper covers the role of visionary leadership, the influence of a high-profile board of directors, corporate governance, investor due diligence, and ethical dilemmas in biotech startups.
What was the main goal of Elizabeth Holmes regarding her company?
Holmes intended to disrupt the healthcare industry by making blood testing faster, cheaper, and less invasive through the use of her proprietary 'Edison' technology.
What scientific or business methods did the author utilize?
The author utilized a qualitative case study approach, synthesizing investigative reporting, legal documents, and secondary data to reconstruct the timeline of Theranos' growth and demise.
What is analyzed in the main body of the work?
The main body focuses on the ideation process, the recruitment of influential figures to the board, the strategies used to attract investors, the detection of fraud by whistleblowers, and the subsequent legal downfall.
Which keywords characterize this document?
Key terms include Theranos, Elizabeth Holmes, corporate governance, biotechnology, startup fraud, and investor relations.
How did the board of directors contribute to the company's failure?
The board was criticized for lacking medical or technical expertise, having an advanced average age, and being chosen primarily for their political influence rather than their ability to oversee the firm’s specific business risks.
What role did whistleblowers play in the downfall of the company?
Employees like Tyler Schultz and Erika Cheung were instrumental in exposing the disarray and inaccurate testing results within the laboratories, which eventually prompted investigative journalism and regulatory intervention.
- Arbeit zitieren
- Friederike Berg (Autor:in), 2019, Theranos Healthcare Start-Up. A Case Study, München, GRIN Verlag, https://www.grin.com/document/505693
